Related Experiment Video
Updated: May 16, 2026
13:01
Modified Single-Loop Reconstruction for Pancreaticoduodenectomy
Published on: September 28, 2019
Postresection chemotherapy for pancreatic cancer.
Brandon G Smaglo1, Michael J Pishvaian
1Georgetown University, Washington, DC, USA.
Cancer Journal (Sudbury, Mass.)
|November 29, 2012
Summary
Adjuvant chemotherapy offers a survival benefit for pancreatic cancer patients post-surgery. Research explores optimal agents like gemcitabine and the role of radiation therapy, alongside neoadjuvant approaches.
Area of Science:
- Oncology
- Surgical Oncology
- Gastrointestinal Oncology
Background:
- Adjuvant chemotherapy is crucial in pancreatic cancer management post-resection.
- Existing evidence supports gemcitabine and 5-fluorouracil, with gemcitabine often preferred for tolerability.
- Optimal strategies for adjuvant therapy remain under investigation.
Purpose of the Study:
- To review the evidence for chemotherapy in adjuvant pancreatic cancer treatment.
- To discuss the role of radiation therapy and novel therapeutic approaches.
- To explore treatment timing, comparing neoadjuvant and adjuvant strategies.
Main Methods:
- Review of existing clinical studies and consensus guidelines.
- Analysis of data on chemotherapy agents, radiation therapy, and treatment sequencing.
- Examination of emerging research on novel agents and predictive markers.
Main Results:
- Chemotherapy provides a modest survival benefit in the adjuvant setting.
- Contrasting international preferences exist for concurrent chemoradiation versus chemotherapy alone.
- Neoadjuvant therapy shows survival benefits, but direct comparisons with adjuvant therapy are limited.
Conclusions:
- Chemotherapy is a cornerstone of adjuvant pancreatic cancer care.
- Ongoing research focuses on personalized treatment selection, novel regimens, and optimal timing (neoadjuvant vs. adjuvant).
- Further studies are needed to resolve debates on concurrent radiation and treatment sequencing.
